Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8737357 | Diagnostic Microbiology and Infectious Disease | 2018 | 17 Pages |
Abstract
Posaconazole (PSC) in combination with anidulafungin (AFG) was evaluated in a murine model of pulmonary aspergillosis. Immunosuppressed animals were infected via the nasal cavity with 2 different A. fumigatus strains. The animals received PSC (oral, 20Â mg/kg per day) and/or AFG (i.p., 10Â mg/kg per day) for 7Â days. On Day 8, the mice were euthanized and fungal burdens were determined from the lungs. Survival curves were constructed for mortality analysis. Compared to untreated groups, groups singly treated with PSC or AFG showed a reduced fungal burden in the lungs (PÂ =Â 0.0001-0.006) and prevention of mortality (66.66-83.33% of survival). Combination treatment with PSC and AFG significantly reduced the fungal burden (or sterilized the lungs) compared to the findings in the untreated and monotherapy groups and improved the survival rate to 100%. The PSC and AFG combination therapy was highly effective and should be evaluated in larger-scale experiments.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Laura Bedin Denardi, Francielli Pantella Kunz de Jesus, Jéssica Tairine Keller, Carla Weiblen, Maria Isabel de Azevedo, Vanessa Oliveira, Janio Morais Santurio, Sydney Hartz Alves,